Nesiritide following maze and mitral valve surgery.

Area of Science:

• Cardiology
• Nephrology
• Surgical Research

Background:

• Fluid retention is common after maze and mitral valve surgery, linked to decreased atrial natriuretic peptide (ANP).
• Nesiritide (NES), a synthetic brain natriuretic peptide, shares ANP's diuretic properties.
• This study investigated NES's potential to enhance postoperative diuresis in these patients.

Purpose of the Study:

• To evaluate the efficacy of prophylactic nesiritide infusion in promoting diuresis post-maze and mitral valve surgery.
• To compare key postoperative outcomes, including fluid balance, extubation time, and oxygenation, between NES and placebo groups.

Main Methods:

• A randomized, blinded, prospective pilot study involved 19 patients undergoing maze and mitral surgery.
• Patients received either a 72-hour infusion of nesiritide (0.01 mcg/kg/min) or a placebo post-cardiopulmonary bypass.
• Measurements included diuresis, diuretic use, extubation time, ANP, and Endothelin-1 levels.

Main Results:

• Postoperative ANP levels decreased in both nesiritide and placebo groups.
• No significant differences were observed in diuresis, furosemide dosage, or time to extubation between groups.
• Oxygenation (PaO2/FiO2 ratio) and Endothelin-1 levels showed no significant group differences at key postoperative time points.

Conclusions:

• Prophylactic nesiritide administration did not demonstrate additional diuretic benefits in postoperative mitral/maze patients on a loop diuretic protocol.
• The findings suggest nesiritide may not offer an advantage for fluid management in this specific patient population under current treatment guidelines.